ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1331

Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience

Chee Ken Cheah, Shirish Sangle (Joint First Author) and David D'Cruz, Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, outcome measures and polychondritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Relapsing polychondritis (RP) is a rare autoimmune disorder characterized by cartilage inflammation and damage. Chronic RP may lead to sequelae due to cartilage tissue damage. There is no diagnostic test for RP and prompt diagnosis remains a challenge due to the marked variation in initial clinical presentation. We describe disease patterns amongst patients with RP, and identify factors that correlate with diagnostic delay and poor outcome.

Methods: This was a retrospective cohort study of RP patients followed up for 20 years in our systemic vasculitis clinic. Patient data was retrieved from June 1995 until 31stDecember 2015, or until patient’s last follow-up date. Data recorded include patients’ demographic, initial clinical presentations, therapeutic regimes, and long-term outcome. Data analysis was performed using SPSS Version 23.0

Results: 45 patients were identified. 68.9% were female. 39 patients (86.7%) were Caucasian, 5 (11.1%) Afro-Caribbean and 1 (2.2%) Asian. Median age of disease onset was 39.0 (29.5, 54.0) years. Median age of RP diagnosis was 42.0 (34.5, 60.5) years. Median diagnosis delay was 19.0 (5.0, 65.0) months. Most had ear involvement at presentation (73.3%, n=33), followed by chest wall or peripheral joint pain (57.8%), eyes (53.3%), nose (42.2%), and airways (28.9%). Mean number of initial organ presentation was 2.6 ± 1.04. All patients received steroid as therapeutic agent. There was wide heterogeneity in terms of therapeutic agents used, including methotrexate (31.1%), azathioprine (26.7%), hydroxychloroquine (13.3%), mycophenolate (13.3%), and IV cyclophosphamide (11.1%). Mean number of drugs used at any time was 1.9 ± 1.00. Long-term sequelae involved chronic pain (64.4%) and drugs related complications (57.8%). 57.8% had ears damages, followed by eyes damages (42.2%), and airway damages (40%). Mean number of organ damages was 1.7 ± 1.37. Higher number of initial organ presentation (r= 0.34, p= 0.022) and younger age of disease onset (r= -0.40, p= 0.006) correlated with diagnosis delay. Male gender correlated with airway involvement (r= 0.42, p= 0.004). There was positive correlation between airway involvement with higher number of organ damage (r= 0.30, p= 0.047). A weak correlation was noted between initial involvement of chest wall or peripheral joint pain with chronic pain complication (r= 0.34, p= 0.024). 30 patients (66.7%) remained under active follow-up, with 11 patients (24.4%) lost to follow-up, and 4 deaths occurred with cause unknown (8.9%).

Conclusion: Our study revealed higher number of initial organ presentation, and younger age of disease onset correlated with potential diagnosis delay. Male gender with airway involvements correlated with higher number of organ damages and poorer outcome. Multicenter registries may lead to a better understanding of this disease.


Disclosure: C. K. Cheah, None; S. Sangle (Joint First Author), None; D. D'Cruz, AstraZeneca, 5,Eli Lilly and Company, 5,GlaxoSmithKline, 5,Roche Pharmaceuticals, 5.

To cite this abstract in AMA style:

Cheah CK, Sangle (Joint First Author) S, D'Cruz D. Disease Patterns and Long Term Outcome Amongst Patients with Relapsing Polychondritis – Single Centre Experience [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/disease-patterns-and-long-term-outcome-amongst-patients-with-relapsing-polychondritis-single-centre-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-patterns-and-long-term-outcome-amongst-patients-with-relapsing-polychondritis-single-centre-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology